Back to all news
Precision Psychiatry Symposium Explores Imaging, AI, and Novel Therapies for Schizophrenia
Virginia Tech hosts a symposium focusing on precision psychiatry, spotlighting imaging, biomarkers, and AI to improve schizophrenia treatment.
Key Details
- 1Precision Psychiatry Symposium scheduled for September at Virginia Tech brings together clinicians, researchers, and industry leaders.
- 2Key topics include new schizophrenia drugs, emerging biomarkers, use of artificial intelligence, and advances in neuroimaging.
- 3Discussion of Cobenfy (xanomeline and trospium chloride), a recently FDA-approved drug for schizophrenia.
- 4Fralin Biomedical Research Institute at VTC highlighted for its programs in computational psychiatry, cognitive neuroscience, and human neuroimaging.
- 5Sessions will explore novel treatment approaches, direct neuromodulator measurement, and computational brain models.
- 6Speakers represent academia, biotechnology, and pharmaceutical companies.
Why It Matters
Integrating imaging, biomarkers, and AI into psychiatry promises more precise and effective treatment for schizophrenia, reducing the current trial-and-error approach. These advancements could also accelerate the development of targeted therapies and improve patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI Detects Hypertension and Diabetes from 5-Second Facial Videos
A machine-learning algorithm can accurately screen for hypertension and diabetes using brief facial video recordings, offering a contactless diagnostic option.
•EurekAlert
AI Highlights Importance of Thymus Protection During Lung Cancer Radiotherapy
AI analysis reveals that radiation exposure to the thymus during lung cancer treatment may worsen patient outcomes.
•EurekAlert
Deep Learning Enables Single-Shot High-Resolution Lensless Dynamic Imaging
Researchers from NJU and PKU have developed a lensless imaging method using deep learning that reconstructs high-fidelity dynamic images from single shots.